Anorgasmia is a type of sexual dysfunction in which a person cannot achieve orgasm despite adequate stimulation. Anorgasmia is far more common in females (4.6 percent) than in males and is especially rare in younger men. The problem is greater in women who are post-menopausal. In males, it is most closely associated with delayed ejaculation. Anorgasmia can often cause sexual frustration. Causes
The condition is sometimes classified as a psychiatric disorder. However, it can also be caused by physiological problems such as diabetic neuropathy, multiple sclerosis, Parkinsons disease, genital mutilation on any gender, complications from genital surgery, pelvic trauma (such as from a straddle injury caused by falling on the bars of a climbing frame, bicycle or gymnastics beam), hormonal imbalances, total hysterectomy, spinal cord injury, cauda equina syndrome, uterine embolisation, childbirth trauma (vaginal tearing through the use of forceps or suction or a large or unclosed episiotomy), vulvodynia and cardiovascular disease. Drugs-induced
A common cause of anorgasmia, in both women and men, is the use of anti-depressants, particularly selective serotonin reuptake inhibitors (SSRIs). Though reporting of anorgasmia as a side effect of SSRIs is not precise, studies have found that 17–41% of users of such medications are affected by some form of sexual dysfunction.Another cause of anorgasmia is cocaine use and opiate addiction, particularly to heroin. Primary anorgasmia
Primary anorgasmia is a condition where one has never experienced an orgasm. This is significantly more common in women, although it can occur in men who lack the gladipudendal (bulbocavernosus) reflex.
Epidemiology
The number of cases of vaginal yeast infection is not entirely clear because it is not a reportable disease and it is commonly diagnosed clinically without laboratory confirmation.Candidiasis is one of the three most common vaginal infections along with bacterial vaginosis and trichomonas. About 75% of women have at least one infection in their lifetime, 40%–45% will have two or more episodes, and approximately 20% of women get an infection yearly. Research
Vaccines that target C. albicans are under active development since several years. Phase 2 results published in June 2018 showed a safe and high immunogenicity of the NDV-3A vaccine candidate. == References ==